The Brussels International Declaration on Lipoprotein(a) Testing and Management
Language English Country Ireland Media print-electronic
Document type Journal Article
PubMed
40340180
DOI
10.1016/j.atherosclerosis.2025.119218
PII: S0021-9150(25)00116-9
Knihovny.cz E-resources
- Keywords
- Cardiovascular risk, Cardiovascular risk evaluation, Lipoprotein(a), Patient engagement, Screening,
- MeSH
- Biomarkers blood MeSH
- Risk Assessment MeSH
- Cardiovascular Diseases * blood diagnosis prevention & control epidemiology MeSH
- Consensus MeSH
- Humans MeSH
- Lipoprotein(a) * blood MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Biomarkers MeSH
- Lipoprotein(a) * MeSH
There is striking evidence that a high lipoprotein(a) [Lp(a)] concentration is a strong, independent, and causal cardiovascular risk factor. However, Lp(a) testing rates are very low (1 %-2 %) despite the fact that 1 in 5 individuals have elevated Lp(a) concentrations. The Brussels International Declaration on Lp(a) Testing and Management was co-created by the Lp(a) International Task Force and global leaders at the Lp(a) Global Summit, held in Brussels, Belgium, on March 24-25, 2025. The event, organized by FH Europe Foundation, brought together scientific experts, people with the lived experience of elevated Lp(a) and policy makers from the European Institutions and World Health Organization. The World Heart Federation, Global Heart Hub, and European Alliance for Cardiovascular Health and scientific organizations such as European Atherosclerosis Society, and International Atherosclerosis Society were formal partners. The Summit was hosted by a Member of the European Parliament, Romana Jerković, and held under the patronage of the Polish presidency of the Council of the European Union. The Declaration calls for 1) integration of Lp(a) testing and management into Global, European and National Cardiovascular Health Plans; 2) appropriate investment, policy and programmes in targeting Lp(a) testing and management based on a recent study demonstrating the substantial overall cost-saving to health systems across the globe; 3) political commitment to mandate systematic Lp(a) testing at least once during a person's lifetime, ideally at an early age, with full reimbursement; 4) incorporation of Lp(a) test results in the context of a person's cardiovascular risk assessment, with development of personalised cardiovascular health roadmaps as needed, without fear of dredit aiscrimination; 5) investment in public and healthcare professional education to increase awareness of Lp(a) and its impact on cardiovascular health.
Department of Cardiovascular Medicine Kyorin University Faculty of Medicine Mitaka Japan
Department of Internal Medicine and Pediatrics Ghent University Hospital Ghent Belgium
Department of Laboratory Medicine and Pathology Mayo Clinic Rochester MN USA
Department of Public Health and Primary Care Imperial College London London UK
European Regional and Local Health Authorities Brussels Belgium
FASTA University School of Medicine Pharmacology and Research Department Mar Del Plata Argentina
FH Europe Foundation Amsterdam Netherlands
Global Heart Hub Galway Ireland
Hospital Israelita Albert Einstein and University of Sao Paulo Brazil
Institute of Science Tokyo Depatment of Medical Genetics Tokyo Japan
International Atherosclerosis Society Washington DC USA
Lp International Task Force FH Europe Foundation Amsterdam Netherlands
Monash University Victoria Heart Institute Melbourne Australia
Stichting Health Clusternet Amsterdam Netherlands
Zagreb School of Medicine University of Zagreb University Hospital Center Zagreb Zagreb Croatia
References provided by Crossref.org
